Literature DB >> 17039417

Activation of Akt and Erk pathways in medulloblastoma.

Paweł Włodarski1, Wiesława Grajkowska, Magda Łojek, Kamila Rainko, Jarosław Jóźwiak.   

Abstract

Medulloblastoma (MB) is the most common malignant brain tumour in children. Its aetiology is unknown, although several signalling pathways controlling cell proliferation are thought to participate in the progress of the neoplasm. Mutations of the genes encoding proteins participating in the pathways triggered by embryonic growth factors like Sonic hedgehog (Shh) or WNT are often found in MB. Another model of MB development is overexpression or mutation of several types of growth factor receptors, including IGF-IR, EGF-R and PDGFR, that have the ability to activate cellular kinases responsible for promoting cell proliferation. In order to test this hypothesis, in the current paper we tested the activation of two kinases, Akt/PKB (protein kinase B) and Erk (extracellular signal-regulated kinase) and their substrates in 10 sporadic medulloblastoma cases. We show that MBs are a highly heterogeneous group of tumours that show upregulation of various signalling pathways. Nevertheless, both Akt and Erk may contribute to the progression of MB, triggering, at least in some cases, the mTOR (mammalian target of rapamycin) pathway, controlling translation of several cell cycle-related proteins. We hypothesize that Akt and Erk activation may also be associated with downregulation of protein phosphatase 2A (PP2A).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17039417

Source DB:  PubMed          Journal:  Folia Neuropathol        ISSN: 1509-572X            Impact factor:   2.038


  19 in total

1.  Brain cancer stem cells display preferential sensitivity to Akt inhibition.

Authors:  Christine E Eyler; Wen-Chi Foo; Katherine M LaFiura; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Stem Cells       Date:  2008-09-18       Impact factor: 6.277

2.  Long non-coding RNA FAL1 functions as a ceRNA to antagonize the effect of miR-637 on the down-regulation of AKT1 in Hirschsprung's disease.

Authors:  Yang Li; Lingling Zhou; Changgui Lu; Qiyang Shen; Yang Su; Zhengke Zhi; Feng Wu; Hua Zhang; Zechao Wen; Guanglin Chen; Hongxing Li; Yankai Xia; Weibing Tang
Journal:  Cell Prolif       Date:  2018-07-30       Impact factor: 6.831

3.  Decreased miRNA-637 is an unfavorable prognosis marker and promotes glioma cell growth, migration and invasion via direct targeting Akt1.

Authors:  T Que; Y Song; Z Liu; S Zheng; H Long; Z Li; Y Liu; G Wang; Y Liu; J Zhou; X Zhang; W Fang; S Qi
Journal:  Oncogene       Date:  2015-01-19       Impact factor: 9.867

4.  Sorafenib downregulates ERK/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line.

Authors:  Hong Chai; Annie Z Luo; Priya Weerasinghe; Robert E Brown
Journal:  Int J Clin Exp Pathol       Date:  2010-04-23

5.  A novel role of HLA class I in the pathology of medulloblastoma.

Authors:  Courtney Smith; Mariarita Santi; Bhargavi Rajan; Elisabeth J Rushing; Mi Rim Choi; Brian R Rood; Robert Cornelison; Tobey J MacDonald; Stanislav Vukmanovic
Journal:  J Transl Med       Date:  2009-07-12       Impact factor: 5.531

Review 6.  The molecular genetics of medulloblastoma: an assessment of new therapeutic targets.

Authors:  Carlos G Carlotti; Christian Smith; James T Rutka
Journal:  Neurosurg Rev       Date:  2008-06-12       Impact factor: 3.042

7.  mTOR pathway as a potential target in a subset of human medulloblastoma.

Authors:  Tímea Pócza; Anna Sebestyén; Eszter Turányi; Tibor Krenács; Agnes Márk; Tamás Béla Sticz; Zsuzsanna Jakab; Péter Hauser
Journal:  Pathol Oncol Res       Date:  2014-04-16       Impact factor: 3.201

Review 8.  The rationale for targeted therapies in medulloblastoma.

Authors:  Tobey J MacDonald; Dolly Aguilera; Robert C Castellino
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

9.  Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics.

Authors:  Xi Huang; Adrian M Dubuc; Rintaro Hashizume; Jim Berg; Ye He; Ji Wang; Chin Chiang; Michael K Cooper; Paul A Northcott; Michael D Taylor; Michael J Barnes; Tarik Tihan; Justin Chen; Christopher S Hackett; William A Weiss; C David James; David H Rowitch; Marc A Shuman; Yuh Nung Jan; Lily Yeh Jan
Journal:  Genes Dev       Date:  2012-08-01       Impact factor: 11.361

10.  Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas.

Authors:  Fan Yang; Timothy E Van Meter; Ralf Buettner; Michael Hedvat; Wei Liang; Claudia M Kowolik; Nilesh Mepani; Janni Mirosevich; Sangkil Nam; Mike Y Chen; Gary Tye; Mark Kirschbaum; Richard Jove
Journal:  Mol Cancer Ther       Date:  2008-11       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.